Amycretin) Several leading pharmaceutical companies are advancing oral GLP-1 receptor agonists aimed at delivering powerful, needle-free alternatives to injections
With the caveat that you'll gain a little bit back but not a huge amount." For its part, Calibrate says it has the interests of its patients at heart, and that it's acknowledging the fact that many of them are not going to stay on weight-loss drugs for life, given supply-chain shortages, insurance coverage limits, medication costs, issues with side effects, or them not wanting to stay on a medication forever
The case report literature on GLP-1 agonists and anorgasmia identifies decreased norepinephrine signaling as a potential contributor to orgasmic dysfunction, which represents a separate but related concern from decreased desire
Cagrilintide: What the Evidence Actually Shows The pivotal standalone human dataset for cagrilintide is a multicentre, randomised, double-blind, placebo- and active-controlled, dose-finding Phase 2 trial in people with overweight or obesity
In a recent trial studying the effectiveness of tirzepatide (Zepbound) for weight loss, participants lost an average of 20.9% of their body weight at 36 weeks
